A double-blind, randomized, placebo-controlled, dose-escalating Phase I trial to determine the safety, pharmacokinetic parameters, and clinical effects of single subcutaneous injections of IGX12 in healthy female and male participants

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504671-24-00

Acronym

PRO-2022-009

Enrollment

Registered

2023-09-15

Start date

2023-09-22

Completion date

2025-07-25

Last updated

2024-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Men and women infertility

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Germany

None listed

Source: EU CTIS · Data processed: Feb 4, 2026